Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Monotherapy in R/R DLBCL and cFL in the Outpatient Setting
NCT05451810Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Aug 2022
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Genmab. Started Aug 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05451810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451810.